Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800681950> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2800681950 abstract "TPS8618 Background: PI3K-delta is critical for activation, proliferation and survival of B cells and plays a role in homing and retention in lymphoid tissues. PI3Kδ signaling is hyperactive in many B-cell malignancies. Idelalisib is a first-in-class, selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and inhibits homing and retention of malignant B cells in lymphoid tissues (Lannutti et al, 2011). Phase I trials demonstrated that idelalisib is highly active in pts with heavily pretreated iNHL: pts experienced reductions in disease-associated chemokines, profound and rapid reductions in lymphadenopathy, and durable clinical benefit with an acceptable safety profile (de Vos et al, 2011). Methods: 450 pts with previously treated iNHL, who have measurable lymphadenopathy, require therapy for iNHL, have received prior anti-CD20-antibody-containing therapy and chemotherapy, and who have iNHL that is not refractory to bendamustine (B) are randomized in a 2:1 ratio into Arm A or B. In Arm A, pts receive idelalisib at 150 mg BID continuously + rituximab (R) at 375 mg/m 2 every 28 days for 6 cycles + B at 90 mg/m 2 on days 1 and 2 of each 28-d cycle. In Arm B, pts receive placebo BID instead of idelalisib. Stratification factors include tumor type (follicular lymphoma vs others), tumor burden (high vs low), and time since completion of last prior therapy for iNHL (<18 months vs ≥18 months). The primary endpoint is PFS, and key secondary endpoints include CR rate, ORR, lymph node response rate, and OS. This is an event-driven trial and primary endpoint evaluation will be based on independent central review. For the primary efficacy analysis, the difference in PFS between the treatment arms will be assessed in the ITT analysis set using Kaplan-Meier methods and the stratified log-rank test. The study opened for enrollment in Dec 2012 (NCT01732926). Clinical trial information: NCT01732926." @default.
- W2800681950 created "2018-05-17" @default.
- W2800681950 creator A5016136114 @default.
- W2800681950 creator A5025865972 @default.
- W2800681950 creator A5026641386 @default.
- W2800681950 creator A5027453053 @default.
- W2800681950 creator A5042317118 @default.
- W2800681950 creator A5046049357 @default.
- W2800681950 creator A5048838398 @default.
- W2800681950 creator A5064196229 @default.
- W2800681950 creator A5081213752 @default.
- W2800681950 creator A5087985272 @default.
- W2800681950 creator A5091882595 @default.
- W2800681950 date "2013-05-20" @default.
- W2800681950 modified "2023-09-22" @default.
- W2800681950 title "A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)." @default.
- W2800681950 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.tps8618" @default.
- W2800681950 hasPublicationYear "2013" @default.
- W2800681950 type Work @default.
- W2800681950 sameAs 2800681950 @default.
- W2800681950 citedByCount "5" @default.
- W2800681950 countsByYear W28006819502014 @default.
- W2800681950 countsByYear W28006819502015 @default.
- W2800681950 countsByYear W28006819502018 @default.
- W2800681950 crossrefType "journal-article" @default.
- W2800681950 hasAuthorship W2800681950A5016136114 @default.
- W2800681950 hasAuthorship W2800681950A5025865972 @default.
- W2800681950 hasAuthorship W2800681950A5026641386 @default.
- W2800681950 hasAuthorship W2800681950A5027453053 @default.
- W2800681950 hasAuthorship W2800681950A5042317118 @default.
- W2800681950 hasAuthorship W2800681950A5046049357 @default.
- W2800681950 hasAuthorship W2800681950A5048838398 @default.
- W2800681950 hasAuthorship W2800681950A5064196229 @default.
- W2800681950 hasAuthorship W2800681950A5081213752 @default.
- W2800681950 hasAuthorship W2800681950A5087985272 @default.
- W2800681950 hasAuthorship W2800681950A5091882595 @default.
- W2800681950 hasConcept C126322002 @default.
- W2800681950 hasConcept C142724271 @default.
- W2800681950 hasConcept C143998085 @default.
- W2800681950 hasConcept C204787440 @default.
- W2800681950 hasConcept C27081682 @default.
- W2800681950 hasConcept C2777938653 @default.
- W2800681950 hasConcept C2778461978 @default.
- W2800681950 hasConcept C2778714382 @default.
- W2800681950 hasConcept C2779260929 @default.
- W2800681950 hasConcept C2779338263 @default.
- W2800681950 hasConcept C2779878957 @default.
- W2800681950 hasConcept C2780653079 @default.
- W2800681950 hasConcept C2781442060 @default.
- W2800681950 hasConcept C31760486 @default.
- W2800681950 hasConcept C535046627 @default.
- W2800681950 hasConcept C71924100 @default.
- W2800681950 hasConceptScore W2800681950C126322002 @default.
- W2800681950 hasConceptScore W2800681950C142724271 @default.
- W2800681950 hasConceptScore W2800681950C143998085 @default.
- W2800681950 hasConceptScore W2800681950C204787440 @default.
- W2800681950 hasConceptScore W2800681950C27081682 @default.
- W2800681950 hasConceptScore W2800681950C2777938653 @default.
- W2800681950 hasConceptScore W2800681950C2778461978 @default.
- W2800681950 hasConceptScore W2800681950C2778714382 @default.
- W2800681950 hasConceptScore W2800681950C2779260929 @default.
- W2800681950 hasConceptScore W2800681950C2779338263 @default.
- W2800681950 hasConceptScore W2800681950C2779878957 @default.
- W2800681950 hasConceptScore W2800681950C2780653079 @default.
- W2800681950 hasConceptScore W2800681950C2781442060 @default.
- W2800681950 hasConceptScore W2800681950C31760486 @default.
- W2800681950 hasConceptScore W2800681950C535046627 @default.
- W2800681950 hasConceptScore W2800681950C71924100 @default.
- W2800681950 hasLocation W28006819501 @default.
- W2800681950 hasOpenAccess W2800681950 @default.
- W2800681950 hasPrimaryLocation W28006819501 @default.
- W2800681950 hasRelatedWork W1618071166 @default.
- W2800681950 hasRelatedWork W2134861285 @default.
- W2800681950 hasRelatedWork W2272554863 @default.
- W2800681950 hasRelatedWork W2287352866 @default.
- W2800681950 hasRelatedWork W2294562171 @default.
- W2800681950 hasRelatedWork W2320320404 @default.
- W2800681950 hasRelatedWork W2434837205 @default.
- W2800681950 hasRelatedWork W2479900433 @default.
- W2800681950 hasRelatedWork W2516115738 @default.
- W2800681950 hasRelatedWork W2535685431 @default.
- W2800681950 hasRelatedWork W2538575175 @default.
- W2800681950 hasRelatedWork W2597467395 @default.
- W2800681950 hasRelatedWork W2597780462 @default.
- W2800681950 hasRelatedWork W2601443433 @default.
- W2800681950 hasRelatedWork W2605618073 @default.
- W2800681950 hasRelatedWork W2760705548 @default.
- W2800681950 hasRelatedWork W2762543649 @default.
- W2800681950 hasRelatedWork W2802905910 @default.
- W2800681950 hasRelatedWork W2803079541 @default.
- W2800681950 hasRelatedWork W2889677764 @default.
- W2800681950 isParatext "false" @default.
- W2800681950 isRetracted "false" @default.
- W2800681950 magId "2800681950" @default.
- W2800681950 workType "article" @default.